Table 1. Patient characteristics.
| Clinical and pathologic indexes | Training cohort (n=41) | Validation cohort (n=87) | |
|---|---|---|---|
| No. of Patients (%) | No. of Patients (%) | p | |
| Median age, years (range) | 72 (28-87) | 67 (24-86) | 0.016 |
| Gender | |||
| Male | 32 (78.1) | 60 (69.0) | |
| Female | 9 (21.9) | 27 (31.0) | 0.392 |
| Smoking habits | |||
| No | 18 (50.0) | 12 (42.9) | |
| Yes | 18 (50.0) | 16 (57.1) | 0.752 |
| Etiology | |||
| Metabolic syndrome | 8 (19.5) | 5 (5.7) | |
| Alcohol | 6 (14.6) | 6 (6.9) | |
| Viral | 27 (65.8) | 71 (81.7) | |
| Cryptogenic | 0 | 5 (5.7) | 0.017 |
| BCLC stage | |||
| B | 8 (20.0) | 20 (25.9) | |
| C | 32 (80.0) | 57 (74.1) | 0.624 |
| MELD score | |||
| ≤10 | 30 (81.1) | 37 (62.7) | |
| >10 | 7 (18.9) | 22 (37.3) | 0.093 |
| Serum α-FP level | |||
| ≤400 KUI/L | 20 (52.6) | 52 (69.3) | |
| >400 KUI/L | 18 (47.4) | 23 (30.7) | 0.124 |
| Diabetes | |||
| No | 24 (60.0) | 68 (78.2) | |
| Yes | 16 (40.0) | 19 (21.8) | 0.056 |
| Sorafenib dose reduction | |||
| No | 32 (78.1) | 70 (80.5) | |
| Yes | 9 (21.9) | 17 (19.5) | 0.753 |
| Portal vein thrombosis | |||
| No | 21 (70.0%) | 39 (67.2%) | |
| Yes | 9 (30.0%) | 19 (32.8%) | 0.982 |
| Liver cirrhosis | |||
| No | 1 (2.4%) | 2 (2.2%) | |
| Yes | 40 (97.6%) | 85 (97.8%) | 0,954 |
| Disease extension | |||
| Liver only | 23 (69.6%) | 42 (72.4%) | |
| Metastatic disease | 7 (30.4%) | 16 (27.6%) | 0.861 |
BCLC: Barcelona-Clinic Liver Cancer; MELD: Model For End-Stage Liver Disease